Beam Therapeutics is developing precision genetic medicines through base editing. Founded by leading scientists in CRISPR gene editing, Beam Therapeutics is pursuing therapies for serious diseases using its proprietary base editing technology, which can make precise edits to single base pairs in DNA and RNA. Headquartered in Cambridge, Massachusetts, the company is backed by F-Prime Capital Partners and ARCH Venture Partners, two of the world’s leading biotech venture capital firms. In addition, Beam Therapeutics has already raised a total of $87 million in Series A round.
The human genome is made up of billions of nucleobases, or 'bases,' represented by the letters A, G, T, and C. Beam’s base editing technology can precisely target and make specific edits to a single base in DNA or RNA, without cutting or disrupting the gene. Base editors have the potential to repair disease-causing point mutations, write in protective genetic variations, or modulate the expression or function of disease-causing genes. Beam Therapeutics is committed to developing base editors as a new class of precision genetic medicines that can treat or cure diseases affecting patients’ lives.
Beam Therapeutics is launching to develop precision genetic medicines that make edits to individual base pairs in the genetic code. Co-founded by scientific pioneers known for advancing CRISPR gene editing, Beam Therapeutics is the first company to pursue development of new therapies using CRISPR base editing technology.
Beam’s research will focus on multiple DNA base editor platforms developed in the lab of David Liu, Ph.D., at Harvard University, as well as on the RNA base editor platform developed by Feng Zhang, Ph.D., at the Broad Institute of MIT and Harvard. DNA is made up of billions of nucleobases, or 'bases,' each represented by a single letter (A, G, T, C), which are subsequently encoded in RNA messages for expression by the cell. Base editors are capable of precisely targeting and directly editing just one base out of billions within the genome, without cutting the DNA or RNA.
Beam Therapeutics aims to use these technologies to generate a broad pipeline of precision genetic medicines that repair disease-causing point mutations, write in protective genetic variations, or modulate the expression or function of disease-causing genes. John Evans, the CEO, explained that Base editors are capable of making single-base changes with high efficiency and unprecedented control. Therefore, Beam Therapeutics has assembled the key technologies in base editing and is dedicated to establishing base editors as a new therapeutic option for patients with serious diseases.